The glucagon-like peptide-1 analogue liraglutide effectively improves cardiovascular (CV) parameters in patients with type 2 diabetes mellitus

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1560, 2006-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The glucagon-like peptide-1 analogue liraglutide has demonstrated promising properties for once-daily treatment of type-2 diabetes mellitus

By  

Inpharma, Vol. 1, Iss. 1607, 2007-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Treatment of Type 2 diabetes mellitus based on glucagon-like peptide-1

By Holst J.J.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 9, 1999-09 ,pp. : 1409-1415

Informa Healthcare

Access to resources Recommend Favorite

Glucagon-like Peptide-1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents

By Gallwitz Baptist  

Drugs, Vol. 71, Iss. 13, 2011-09 ,pp. : 1675-1688

Adis International

Access to resources Recommend Favorite

Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus

By  

Current Clinical Pharmacology, Vol. 12, Iss. 4, 2018-04 ,pp. : 202-209

Bentham Science Publishers

Access to resources Recommend Favorite

Incretin-Targeting Technologies for Type 2 Diabetes: Dipeptidyl Peptidase IV Inhibitors and Glucagon-Like Peptide-1 Analogs

By Adis International Limited  

Pharmaceutical & Diagnostic Innovation, Vol. 4, Iss. 7, 2006-07 ,pp. : 3-7

Adis International

Access to resources Recommend Favorite